Nasal Spray Live Attenuated Influenza Vaccine Obtains Drug Registration Certificate
August 26, 2025
Source: drugdu
91
On August 25, BCHT(688276) issued an announcement that the company received the nasal spray influenzaDrug registration certificate for live attenuated vaccine.
The company's approved nasal spray live attenuated influenza vaccine can simulate natural influenza virus infection through nasal inoculation , forming the first immune barrier in the respiratory tract to prevent influenza virus invasion.
In the first quarter of 2025, BCHT achieved revenue of 162 million yuan and net profit attributable to shareholders of the parent company of 1.06 million yuan.
https://finance.eastmoney.com/a/202508253493526324.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval December 12, 2025
- Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials December 12, 2025
- The ‘Sweetest’ HPV Vaccine Market is Gone | Haibin Interview December 12, 2025
- InnoCare Pharma announced that its first independently developed next-generation TRK inhibitor, zoletrazinib, has been approved for marketing in China December 12, 2025
- Is PD-1/VEGF dual antibody + ADC becoming the standard configuration? December 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
